It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.
Type
Public
HQ
Alachua, US
Founded
2002
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People at AxoGen

Karen Zaderej

Karen Zaderej

CEO
Gregory G. Freitag

Gregory G. Freitag

CFO&Director

AxoGen Office Locations

AxoGen has an office in Alachua
Alachua, US (HQ)
400 13631 Progress Blvd

AxoGen Metrics

AxoGen Financial Metrics

Revenue (2016)

$41.1 m

Revenue growth (2015-16), %

50%

Gross profit

$34.6 m

Gross profit margin (2016), %

84%

Net income (2016)

($14.4 m)

Market capitalization (28-Apr-2017)

$402.8 m

Closing share price (28-Apr-2017)

$12.2

Cash (31-Dec-2016)

$30 m
AxoGen's current market capitalization is $402.8 m.
AxoGen's revenue was reported to be $41.1 m in FY, 2016 which is a 50% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$10.9 m$16.8 m$27.3 m$41.1 m

Revenue growth, %

54%63%50%

Cost of goods sold

$2.4 m$3.4 m$4.8 m$6.5 m

Gross profit

$8.5 m$13.4 m$22.5 m$34.6 m

Gross profit Margin, %

78%80%82%84%

Operating expense total

$15.7 m$19.7 m$26.9 m$42.8 m

EBIT

($9.6 m)($9.8 m)($9.3 m)($8.1 m)

EBIT margin, %

(88%)(58%)(34%)(20%)

Interest expense

($4.8 m)($6.8 m)($4 m)($5.4 m)

Pre tax profit

($14.6 m)

Income tax expense

Net Income

($14.6 m)($17.7 m)($13.4 m)($14.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$20.1 m$8.2 m$25.9 m$30 m

Accounts Receivable

Inventories

$3.4 m$3.2 m$3.9 m$5.5 m

Current Assets

$25.7 m$14.4 m$35.1 m$44 m

PP&E

$381.7 k$619 k$970.9 k$1.5 m

Total Assets

$27.7 m$16.4 m$37.5 m$46.4 m

Accounts Payable

$2.1 m$2.4 m$3.7 m$7 m

Current Liabilities

$2.1 m$2.4 m$3.7 m$11.1 m

Additional Paid-in Capital

$72.4 m$78.7 m$111.4 m$132.5 m

Retained Earnings

($72.4 m)($90.1 m)($103.5 m)($117.9 m)

Total Equity

$136.6 k($11.2 m)$8.2 m$14.9 m

Financial Leverage

202.6 x-1.5 x4.6 x3.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($14.6 m)($17.7 m)($13.4 m)($14.4 m)

Depreciation and Amortization

$138.3 k$198.9 k$249 k

Accounts Receivable

($902.2 k)($1 m)($2 m)

Inventories

($247.3 k)$184.8 k($720.3 k)$5.5 m

Accounts Payable

$430.6 k$498.3 k$1.1 m$7 m

Cash From Operating Activities

($10.4 m)($10.5 m)($13.1 m)

Purchases of PP&E

($178.8 k)($542 k)($408.8 k)

Cash From Investing Activities

($244 k)($594 k)($555.5 k)

Long-term Borrowings

($1.8 m)($1.8 m)

Cash From Financing Activities

$16.9 m$31.3 m

Interest Paid

$1 m$3.9 m$3.5 m

AxoGen Market Value History

AxoGen Job Categories

AxoGen Online Presence

AxoGen Company Life

You may also be interested in